Pharma BD Deal Intelligence

Shanghai Henlius Biotech, Inc. / Amberstone Biosciences, Inc.

2026 · Licensing/Option · $888M · Pending

Amberstone Biosciences and Shanghai Henlius Biotech entered a collaboration and license agreement covering conditionally activated T-cell engagers for solid tumors. Amberstone applies its T-MATE (Tumor Microenvironment Activated ThErapeutics) platform to generate preclinical candidates against up to two targets selected by Henlius; Henlius leads subsequent research, development, manufacturing and commercialization worldwide. Henlius pays USD 4 million upfront for worldwide exclusive rights, with up to USD 884.16 million in milestones (up to USD 232.16 million in research fees and development/regulatory milestones, plus up to USD 652 million in sales milestones) and single-digit royalties on net sales.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals